Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novo Nordisk |
---|---|
Information provided by: | Novo Nordisk |
ClinicalTrials.gov Identifier: | NCT00097084 |
This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type 2 diabetes.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Type 2 |
Drug: insulin detemir Drug: insulin glargine Drug: insulin aspart |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes |
Estimated Enrollment: | 300 |
Study Start Date: | September 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arkansas | |
Novo Nordisk Clinical Trial Call Center | |
Little Rock, Arkansas, United States, 72204 | |
United States, California | |
Novo Nordisk Clinical Trial Call Center | |
Santa Ana, California, United States, 92705 | |
Novo Nordisk Clinical Trial Call Center | |
Inglewood, California, United States, 90301 | |
Novo Nordisk Clinical Trial Call Center | |
San Francisco, California, United States, 94143-0728 | |
Novo Nordisk Clinical Trial Call Center | |
Spring Valley, California, United States, 91978 | |
United States, Florida | |
Novo Nordisk Clinical Trial Call Center | |
Melbourne, Florida, United States, 32901 | |
Novo Nordisk Clinical Trial Call Center | |
Orlando, Florida, United States, 32804 | |
Novo Nordisk Clinical Trial Call Center | |
Vero Beach, Florida, United States, 32960 | |
Novo Nordisk Clinical Trial Call Center | |
New Port Richey, Florida, United States, 34652 | |
Novo Nordisk Clinical Trial Call Center | |
Jacksonville, Florida, United States, 32205 | |
Novo Nordisk Clinical Trial Call Center | |
Winter Park, Florida, United States, 32789 | |
Novo Nordisk Clinical Trial Call Center | |
Boca Raton, Florida, United States, 33433 | |
United States, Georgia | |
Novo Nordisk Clinical Trial Call Center | |
Athens, Georgia, United States, 30606 | |
United States, Idaho | |
Novo Nordisk Clinical Trial Call Center | |
Idaho Falls, Idaho, United States, 83404 | |
United States, Kansas | |
Novo Nordisk Clinical Trial Call Center | |
Topeka, Kansas, United States, 66606 | |
United States, Nebraska | |
Novo Nordisk Clinical Trial Call Center | |
Omaha, Nebraska, United States, 68131 | |
United States, Nevada | |
Novo Nordisk Clinical Trial Call Center | |
Las Vegas, Nevada, United States, 89109 | |
United States, New Jersey | |
Novo Nordisk Clinical Trial Call Center | |
Berlin, New Jersey, United States, 08009 | |
United States, North Carolina | |
Novo Nordisk Clinical Trial Call Center | |
Asheville, North Carolina, United States, 28801 | |
United States, Pennsylvania | |
Novo Nordisk Clinical Trial Call Center | |
Philadelphia, Pennsylvania, United States, 19107 | |
Novo Nordisk Clinical Trial Call Center | |
Hermitage, Pennsylvania, United States, 16148 | |
United States, Texas | |
Novo Nordisk Clinical Trial Call Center | |
San Antonio, Texas, United States, 78237 | |
Novo Nordisk Clinical Trial Call Center | |
Dallas, Texas, United States, 75230 | |
United States, Virginia | |
Novo Nordisk Clinical Trial Call Center | |
Richmond, Virginia, United States, 23249 | |
Novo Nordisk Clinical Trial Call Center | |
Norfolk, Virginia, United States, 23462 | |
United States, Washington | |
Novo Nordisk Clinical Trial Call Center | |
Tacoma, Washington, United States, 98405 | |
Finland | |
Espoo, Finland | |
France | |
Venissieux, France | |
Norway | |
Sarpsborg, Norway | |
Sweden | |
Lund, Sweden |
Study Director: | Per Clauson, MD, PhD | Novo Nordisk |
Responsible Party: | Novo Nordisk A/S ( Public Access to Clinical Trials ) |
Study ID Numbers: | NN304-1431, EudraCT No: 2004-000087-27 |
Study First Received: | November 17, 2004 |
Last Updated: | March 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00097084 History of Changes |
Health Authority: | France: Afssaps - French Health Products Safety Agency; Finland: National Agency for Medicines; Norway: Norwegian Medicines Agency; Sweden: Medical Products Agency; United States: Food and Drug Administration |
Diabetes Mellitus, Type II |
Hypoglycemic Agents Metabolic Diseases Diabetes Mellitus, Type 2 Insulin, Asp(B28)- Glargine Diabetes Mellitus |
Endocrine System Diseases Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder Insulin |
Hypoglycemic Agents Metabolic Diseases Physiological Effects of Drugs Diabetes Mellitus, Type 2 Glargine Insulin, Asp(B28)- |
Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Pharmacologic Actions Insulin |